These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

106 related articles for article (PubMed ID: 9097909)

  • 1. Circulating levels of soluble CD30 are increased in patients with systemic sclerosis (SSc) and correlate with serological and clinical features of the disease.
    Giacomelli R; Cipriani P; Lattanzio R; Di Franco M; Locanto M; Parzanese I; Passacantando A; Ciocci A; Tonietti G
    Clin Exp Immunol; 1997 Apr; 108(1):42-6. PubMed ID: 9097909
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Serum levels of soluble CD30 are increased in ulcerative colitis (UC) but not in Crohn's disease (CD).
    Giacomelli R; Passacantando A; Parzanese I; Vernia P; Klidara N; Cucinelli F; Lattanzio R; Santori E; Cipriani P; Caprilli R; Tonietti G
    Clin Exp Immunol; 1998 Mar; 111(3):532-5. PubMed ID: 9528894
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Circulating levels of soluble CD30 are increased in patients with localized scleroderma and correlated with serological and clinical features of the disease.
    Ihn H; Yazawa N; Kubo M; Yamane K; Sato S; Fujimoto M; Kikuchi K; Soma Y; Tamaki K
    J Rheumatol; 2000 Mar; 27(3):698-702. PubMed ID: 10743811
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Expression of CD30 mRNA, CD30L mRNA and a variant form of CD30 mRNA in restimulated peripheral blood mononuclear cells (PBMC) of patients with helminthic infections resembling a Th2 disease.
    Kilwinski J; Berger T; Mpalaskas J; Reuter S; Flick W; Kern P
    Clin Exp Immunol; 1999 Jan; 115(1):114-9. PubMed ID: 9933429
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Different profile of cytokine production in patients with systemic sclerosis and association with clinical manifestations.
    Dantas AT; Almeida AR; Sampaio MCPD; Cordeiro MF; Oliveira PSS; Mariz HA; Pereira MC; Rego MJBM; Pitta IDR; Duarte ALBP; Pitta MGDR
    Immunol Lett; 2018 Jun; 198():12-16. PubMed ID: 29601941
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Increased release of soluble CD163 by the peripheral blood mononuclear cells is associated with worse prognosis in patients with systemic sclerosis.
    Bielecki M; Kowal K; Lapinska A; Chyczewski L; Kowal-Bielecka O
    Adv Med Sci; 2013; 58(1):126-33. PubMed ID: 23640944
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Increased frequency of in vivo hprt gene-mutated T cells in the peripheral blood of patients with systemic sclerosis.
    Sfikakis PP; Tesar J; Theocharis S; Klipple GL; Tsokos GC
    Ann Rheum Dis; 1994 Feb; 53(2):122-7. PubMed ID: 8129457
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Spontaneous CD30 mRNA expression in peripheral blood mononuclear cells from atopic patients with high IgE serum levels.
    Esnault S; Benbernou N; Lavaud F; Guenounou M
    Clin Exp Immunol; 1996 Oct; 106(1):67-72. PubMed ID: 8870700
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Peripheral T lymphocytes from patients with early systemic sclerosis co-cultured with autologous fibroblasts undergo an oligoclonal expansion similar to that occurring in the skin.
    De Palma R; Del Galdo F; Lupoli S; Altucci P; Abbate G; Valentini G
    Clin Exp Immunol; 2006 Apr; 144(1):169-76. PubMed ID: 16542379
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Resistance to apoptosis in circulating alpha/beta and gamma/delta T lymphocytes from patients with systemic sclerosis.
    Cipriani P; Fulminis A; Pingiotti E; Marrelli A; Liakouli V; Perricone R; Pignone A; Matucci-Cerinic M; Giacomelli R
    J Rheumatol; 2006 Oct; 33(10):2003-14. PubMed ID: 17014016
    [TBL] [Abstract][Full Text] [Related]  

  • 11. High levels of the soluble form of CD30 molecule in rheumatoid arthritis (RA) are expression of CD30+ T cell involvement in the inflamed joints.
    Gerli R; Muscat C; Bistoni O; Falini B; Tomassini C; Agea E; Tognellini R; Biagini P; Bertotto A
    Clin Exp Immunol; 1995 Dec; 102(3):547-50. PubMed ID: 8536371
    [TBL] [Abstract][Full Text] [Related]  

  • 12. T and NK Cell Phenotypic Abnormalities in Systemic Sclerosis: a Cohort Study and a Comprehensive Literature Review.
    Almeida I; Silva SV; Fonseca AR; Silva I; Vasconcelos C; Lima M
    Clin Rev Allergy Immunol; 2015 Dec; 49(3):347-69. PubMed ID: 26445774
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Nerve growth factor and neuropeptides circulating levels in systemic sclerosis (scleroderma).
    Matucci-Cerinic M; Giacomelli R; Pignone A; Cagnoni ML; Generini S; Casale R; Cipriani P; Del Rosso A; Tirassa P; Konttinen YT; Kahaleh BM; Fan PS; Paoletti M; Marchesi C; Cagnoni M; Aloe L
    Ann Rheum Dis; 2001 May; 60(5):487-94. PubMed ID: 11302871
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Adhesion of peripheral blood mononuclear cells to vascular endothelium in patients with systemic sclerosis (scleroderma).
    Rudnicka L; Majewski S; Blaszczyk M; Skiendzielewska A; Makiela B; Skopinska M; Jablonska S
    Arthritis Rheum; 1992 Jul; 35(7):771-5. PubMed ID: 1622415
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Increased production of a proliferation-inducing ligand (APRIL) by peripheral blood mononuclear cells is associated with antitopoisomerase I antibody and more severe disease in systemic sclerosis.
    Bielecki M; Kowal K; Lapinska A; Bernatowicz P; Chyczewski L; Kowal-Bielecka O
    J Rheumatol; 2010 Nov; 37(11):2286-9. PubMed ID: 20810514
    [TBL] [Abstract][Full Text] [Related]  

  • 16. CD1a+ survivin+ dendritic cell infiltration in dermal lesions of systemic sclerosis.
    Mokuda S; Miyazaki T; Ubara Y; Kanno M; Sugiyama E; Takasugi K; Masumoto J
    Arthritis Res Ther; 2015 Sep; 17():275. PubMed ID: 26419626
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Characterisation of the immune response to type I collagen in scleroderma.
    Warrington KJ; Nair U; Carbone LD; Kang AH; Postlethwaite AE
    Arthritis Res Ther; 2006; 8(4):R136. PubMed ID: 16879746
    [TBL] [Abstract][Full Text] [Related]  

  • 18. In situ expression and serum levels of tumor necrosis factor-alpha receptors in patients with early stages of systemic sclerosis.
    Gruschwitz MS; Albrecht M; Vieth G; Haustein UF
    J Rheumatol; 1997 Oct; 24(10):1936-43. PubMed ID: 9330935
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Soluble CD8 antigen in systemic sclerosis.
    Famularo G; Giacomelli R; Sacchetti S; Danese C; Luciani AM; Perego MA; Tonietti G
    J Clin Lab Immunol; 1990 Jul; 32(3):109-12. PubMed ID: 1966946
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A macrophage marker, Siglec-1, is increased on circulating monocytes in patients with systemic sclerosis and induced by type I interferons and toll-like receptor agonists.
    York MR; Nagai T; Mangini AJ; Lemaire R; van Seventer JM; Lafyatis R
    Arthritis Rheum; 2007 Mar; 56(3):1010-20. PubMed ID: 17328080
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.